EP2971288A4 - Compositions, procédés et systèmes informatiques associés à la production et l'administration de lymphocytes t modifiés - Google Patents

Compositions, procédés et systèmes informatiques associés à la production et l'administration de lymphocytes t modifiés

Info

Publication number
EP2971288A4
EP2971288A4 EP14773595.5A EP14773595A EP2971288A4 EP 2971288 A4 EP2971288 A4 EP 2971288A4 EP 14773595 A EP14773595 A EP 14773595A EP 2971288 A4 EP2971288 A4 EP 2971288A4
Authority
EP
European Patent Office
Prior art keywords
compositions
cells
making
methods
computer systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14773595.5A
Other languages
German (de)
English (en)
Other versions
EP2971288A1 (fr
Inventor
Roderick A Hyde
Wayne R Kindsvogel
Gary L Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elwha LLC
Original Assignee
Elwha LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/804,224 external-priority patent/US9587237B2/en
Priority claimed from US13/826,803 external-priority patent/US20140274801A1/en
Priority claimed from US13/827,960 external-priority patent/US9499855B2/en
Application filed by Elwha LLC filed Critical Elwha LLC
Publication of EP2971288A1 publication Critical patent/EP2971288A1/fr
Publication of EP2971288A4 publication Critical patent/EP2971288A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
EP14773595.5A 2013-03-14 2014-03-11 Compositions, procédés et systèmes informatiques associés à la production et l'administration de lymphocytes t modifiés Ceased EP2971288A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/804,224 US9587237B2 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified T cells
US13/826,803 US20140274801A1 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified t cells
US13/827,960 US9499855B2 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified T cells
PCT/US2014/023650 WO2014159435A1 (fr) 2013-03-14 2014-03-11 Compositions, procédés et systèmes informatiques associés à la production et l'administration de lymphocytes t modifiés

Publications (2)

Publication Number Publication Date
EP2971288A1 EP2971288A1 (fr) 2016-01-20
EP2971288A4 true EP2971288A4 (fr) 2016-12-07

Family

ID=51625167

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14773595.5A Ceased EP2971288A4 (fr) 2013-03-14 2014-03-11 Compositions, procédés et systèmes informatiques associés à la production et l'administration de lymphocytes t modifiés

Country Status (2)

Country Link
EP (1) EP2971288A4 (fr)
WO (1) WO2014159435A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016019071A8 (pt) 2014-03-11 2021-07-06 Cellectis método para preparar uma célula t engenheirada, célula t engenheirada, e seus usos
CN105985444B (zh) * 2015-02-05 2024-02-13 博生吉安科细胞技术有限公司 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
EP4332115A2 (fr) 2019-04-03 2024-03-06 Precision Biosciences, Inc. Cellules immunitaires génétiquement modifiées comprenant un arnsh adapté au microarn (shrnamir)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118661A1 (fr) * 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut Bibliotheques du recepteur de cellule T
US20050026199A1 (en) * 2000-01-21 2005-02-03 Shaw Sandy C. Method for identifying biomarkers using Fractal Genomics Modeling
US7094555B2 (en) * 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20100017370A1 (en) * 2006-10-11 2010-01-21 Antitope Limited T cell epitope databases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAMERON J TURTLE ET AL: "Engineered T cells for anti-cancer therapy", CURRENT OPINION IN IMMUNOLOGY., vol. 24, no. 5, 18 July 2012 (2012-07-18), GB, pages 633 - 639, XP055272888, ISSN: 0952-7915, DOI: 10.1016/j.coi.2012.06.004 *
CHRISTOPHER C KLOSS ET AL: "Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells", NATURE BIOTECHNOLOGY, vol. 31, no. 1, 16 December 2012 (2012-12-16), pages 71 - 75, XP055130697, ISSN: 1087-0156, DOI: 10.1038/nbt.2459 *
KEN-ICHI HANADA ET AL: "nature biotechnology volume 31 number 1 JAnuArY 2013 33", 1 January 2013 (2013-01-01), XP055290041, Retrieved from the Internet <URL:http://www.nature.com/nbt/journal/v31/n1/pdf/nbt.2471.pdf> [retrieved on 20160720] *
SCOTT WILKIE ET AL: "Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 32, no. 5, 17 April 2012 (2012-04-17), pages 1059 - 1070, XP035113362, ISSN: 1573-2592, DOI: 10.1007/S10875-012-9689-9 *
See also references of WO2014159435A1 *
UTTENTHAL BENJAMIN J ET AL: "Challenges in T cell receptor gene therapy.", THE JOURNAL OF GENE MEDICINE JUN 2012, vol. 14, no. 6, June 2012 (2012-06-01), pages 386 - 399, XP002760096, ISSN: 1521-2254 *

Also Published As

Publication number Publication date
WO2014159435A1 (fr) 2014-10-02
EP2971288A1 (fr) 2016-01-20

Similar Documents

Publication Publication Date Title
IL272324B (en) Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
HK1222741A1 (zh) 改進的燃料電池系統和方法
LT3066201T (lt) Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
EP3063545A4 (fr) Systèmes et procédés de traitement de données relatives à l&#39;utilisation d&#39;énergie
EP3055793A4 (fr) Systèmes et procédés d&#39;ajout de métadonnées descriptives à un contenu numérique
SG11201602278YA (en) Virtual computing systems and methods
EP2970909A4 (fr) Procédés et compositions associés à l&#39;activité des lymphocytes t
EP2943591A4 (fr) Procédés et compositions pour le profilage d&#39;expression cellulaire unique
GB201322094D0 (en) Methods and compositions relating to alzheimers disease
IL245524A0 (en) New methods for the production of active tert
EP2971030B8 (fr) Compositions d&#39;oligosaccharide, glycoprotéines et procédés pour produire celles-ci dans des procaryotes
EP2988764A4 (fr) Compositions antipelliculaires et leurs méthodes d&#39;utilisation
SG11201510209SA (en) Cell populations, methods of transdifferention and methods of use thereof
EP2964610A4 (fr) Composition de marquage au 18f à base de vinylsulfone et procédés et utilisations associés
SG11201707615YA (en) Methods and compositions for producing hepatocyte-like cells
PT3066199T (pt) Snorna, composições e utilizações
EP2971288A4 (fr) Compositions, procédés et systèmes informatiques associés à la production et l&#39;administration de lymphocytes t modifiés
HK1213810A1 (zh) 施用和相關的組合物、方法和系統
EP3011336A4 (fr) Procédés, systèmes et composition en rapport avec les troubles nerveux
EP3050265A4 (fr) Distribution de contenu au moyen de relations sociales
EP2992031A4 (fr) Compositions de polycarbonate aliphatiques et procédés associés
GB201319917D0 (en) Accelerator Compositions and Methods
AU2013903254A0 (en) Probiotic compositions and uses thereof (IV)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/00 20110101ALI20160722BHEP

Ipc: C40B 40/02 20060101AFI20160722BHEP

Ipc: C12N 5/0783 20100101ALI20160722BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161108

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20161102BHEP

Ipc: C40B 40/02 20060101AFI20161102BHEP

Ipc: G06F 19/00 20110101ALI20161102BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170928

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190606